|
|
Prepublished online as a Blood First Edition Paper on September 26, 2002; DOI 10.1182/blood-2002-04-1240.

Submitted May 2, 2002
Accepted September 22, 2002
Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells
Kiyotaka Kuzushima*, Naomi Hayashi, Ayumi Kudoh, Yoshiki Akatsuka, Kunio Tsujimura, Yasuo Morishima, and Tatsuya Tsurumi
Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan
Division of Virology, Aichi Cancer Center Research Institute, Nagoya, Japan
Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Nagoya, Japan
* Corresponding author; email: kkuzushi{at}aichi-cc.jp.
We determined CTL epitopes here through screening with a computer-assisted algorithm and an enzyme-linked immunospot (ELISPOT) assay using in vitro-reactivated polyclonal EBV-specific CD8+ T cells as responders. In addition, to confirm that the epitopes were generated after endogenous processing and presentation of the EBV proteins, a novel T cell receptor (TCR) down-regulation assay was introduced, in which a fluorescent tetrameric major histocompatibility complex (MHC)/peptide complex was employed for detecting TCR down-regulation after stimulation with the epitope presented on antigen presenting cells. Through such screening, three HLA A*2402-restricted epitopes were identified; IYVLVMLVL, TYPVLEEMF and DYNFVKQLF derived from LMP2, BRLF1 and BMLF1 proteins, respectively. TCR down-regulation assays disclosed that, in contrast to other two epitopes, IYVLVMLVL was not presented on HLA A24-positive fibroblast cells infected with recombinant vaccinia viruses expressing LMP2. Furthermore, ELISPOT assays with an epitope specific CTL clone demonstrated that the presentation was partially restored by pretreatment of the fibroblast cells with interferon- . The epitope was presented on transporters associated with antigen processing (TAP)-negative T2 cells transfected with plasmids encoding HLA A*2402 and the minimal epitope, indicating that the presentation is TAP-independent. In conclusion, the 3 epitopes thus defined could be useful for study of EBV-specific CD8+ T cell responses among populations positive for HLA A*2402.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Ochi, H. Fujiwara, K. Suemori, T. Azuma, Y. Yakushijin, T. Hato, K. Kuzushima, and M. Yasukawa
Aurora-A kinase: a novel target of cellular immunotherapy for leukemia
Blood,
January 1, 2009;
113(1):
66 - 74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Laughlin, J. D. Miller, E. James, D. Fillos, C. C. Ibegbu, R. S. Mittler, R. Akondy, W. Kwok, R. Ahmed, and G. Nepom
Antigen-Specific CD4+ T Cells Recognize Epitopes of Protective Antigen following Vaccination with an Anthrax Vaccine
Infect. Immun.,
April 1, 2007;
75(4):
1852 - 1860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ito, A. Demachi-Okamura, R. Ohta, Y. Akatsuka, K. Nishida, K. Tsujimura, Y. Morishima, T. Takahashi, and K. Kuzushima
Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells
J. Gen. Virol.,
March 1, 2007;
88(3):
770 - 780.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ito, E. Kondo, A. Demachi-Okamura, Y. Akatsuka, K. Tsujimura, M. Tanimoto, Y. Morishima, T. Takahashi, and K. Kuzushima
Three Immunoproteasome-Associated Subunits Cooperatively Generate a Cytotoxic T-Lymphocyte Epitope of Epstein-Barr Virus LMP2A by Overcoming Specific Structures Resistant to Epitope Liberation
J. Virol.,
January 15, 2006;
80(2):
883 - 890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Miyahara, H. Naota, L. Wang, A. Hiasa, M. Goto, M. Watanabe, S. Kitano, S. Okumura, T. Takemitsu, A. Yuta, et al.
Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE
Clin. Cancer Res.,
August 1, 2005;
11(15):
5581 - 5589.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wada, T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara
Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2
Cancer Res.,
June 1, 2005;
65(11):
4939 - 4946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Wang, H. Chen, X. Jiang, M. Zhang, T. Wan, N. Li, X. Zhou, Y. Wu, F. Yang, Y. Yu, et al.
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein
Blood,
July 1, 2004;
104(1):
200 - 206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Edwards, D. Sitki-Green, D. T. Moore, and N. Raab-Traub
Potential Selection of LMP1 Variants in Nasopharyngeal Carcinoma
J. Virol.,
January 15, 2004;
78(2):
868 - 881.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|